METHODS
LASER-TBM was an open-label, parallel-group, randomized, multiarm, phase 2A trial; participants were randomized to 1 of 3 treatment arms (described below). Investigational drugs were given for the first 56 days of therapy. Primary end point data were collected at day 56. Treatment was subsequently continued per South African national guidance. Participants completed study follow-up at 6 months. Interim analysis for safety was performed by an independent data and safety monitoring board (DSMB) after every 15 participants enrolled. A full version of the study protocol is published elsewhere [